EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle‐invasive bladder cancer: a nationwide population‐based study

Anke Richters iD, Noor van Ginkel, Richard P Meijer, Maurits Wondergem, Ivo Schoots, André N Vis, Lambertus A L M Kiemeney, Bas W G van Rhijn, J Alfred Witjes, Katja K H Aben, Laura S Mertens

BJU International · 2023

DOI: 10.1111/bju.16091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2023. Verfasst von Anke Richters und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To provide insight into the use and staging information on lymph‐node involvement added by fluorodeoxyglucose‐positron emission tomography/computed tomography (FDG‐PET/CT) in patients with muscle‐invasive bladder cancer (MIBC), based on a nationwide population‐based cohort study. Patients and methods We analysed a nationwide cohort of patients with MIBC without signs of distant metastases, newly diagnosed in the Netherlands between November 2017 and October 2019. From this cohort, we selected patients who underwent pre‐treatment staging with CT only or CT and FDG‐PET/CT. The distribution of patients, disease characteristics, imaging findings, nodal status (clinical nodal stage cN0 vs cN+) and treatment were described for each imaging modality group (CT only vs CT and FDG‐PET/CT).

Results

We identified 2731 patients with MIBC: 1888 (69.1%) underwent CT only; 606 (22.2%) underwent CT and FDG‐PET/CT, 237 (8.6%) underwent no CT. Of the patients who underwent CT only, 200/1888 (10.6%) were staged as cN+, vs 217/606 (35.8%) who underwent CT and FDG‐PET/CT. Stratified analysis showed that this difference was found in patients with clinical tumour stage (cT)2 as well as cT3/4 MIBC. Of patients who underwent both imaging modalities and were staged with CT as cN0, 109/498 (21.9%) were upstaged to cN+ based on FDG‐PET/CT. Radical cystectomy (RC) was the most common treatment within both imaging groups. Preoperative chemotherapy was more frequently applied in cN+ disease and in FDG‐PET/CT‐staged patients. Concordance of pathological N stage after upfront RC was higher among patients staged as cN+ with CT and FDG‐PET/CT (50.0% pN+) than those staged as cN+ with only CT (39.3%).

Conclusion

Patients with MIBC who underwent pre‐treatment staging with FDG‐PET/CT were more often staged as lymph node positive, regardless of cT stage. In patients with MIBC who underwent CT and FDG‐PET/CT, FDG‐PET/CT led to clinical nodal upstaging in approximately one‐fifth. Additional imaging findings may influence subsequent treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyUrinary Bladder NeoplasmsHumansFluorodeoxyglucose F18Cohort StudiesPositron-Emission TomographyTomography, X-Ray ComputedNeoplasm StagingMusclesRadiopharmaceuticals

Stichwörter der Autor:innen

Bladder cancerFDG-PET/CTimagingmuscle-invasiveradical cystectomystagingurothelial carcinoma

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
  • Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Urology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Oncologic Urology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Nuclear Medicine, the Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: Anke Richters

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Richters, A., van Ginkel, N., Meijer, R. P., Wondergem, M., Schoots, I., Vis, A. N., Kiemeney, L. A. L. M., van Rhijn, B. W. G., Witjes, J. A., Aben, K. K. H., & Mertens, L. S. (2023). Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle‐invasive bladder cancer: a nationwide population‐based study. BJU International. https://doi.org/10.1111/bju.16091

Vancouver

Richters A, van Ginkel N, Meijer RP, Wondergem M, Schoots I, Vis AN, et al. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle‐invasive bladder cancer: a nationwide population‐based study. BJU International. 2023. doi:10.1111/bju.16091

BibTeX
@article{Richters2023,
  author = {Richters, Anke and van Ginkel, Noor and Meijer, Richard P and Wondergem, Maurits and Schoots, Ivo and Vis, André N and Kiemeney, Lambertus A L M and van Rhijn, Bas W G and Witjes, J Alfred and Aben, Katja K H and Mertens, Laura S},
  title = {Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle‐invasive bladder cancer: a nationwide population‐based study},
  journal = {BJU International},
  year = {2023},
  doi = {10.1111/bju.16091}
}
Kostenlos starten →